Evidence map›Paper›PMID 28042454›Full record

ArticleTherapeutic advances in hematology2017

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.

Sikander Ailawadhi, Luke P Akard, Carole B Miller, Anand Jillella, Daniel J DeAngelo, Solveig G Ericson, Felice Lin, Ghulam Warsi, Jerald Radich

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Sikander AilawadhiDivision of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Luke P AkardDepartment of Hematology, Indiana Blood and Marrow Transplantation, Indianapolis, IN, USA.
Carole B MillerDepartments of Internal Medicine and Medical Oncology, St. Agnes Hospital, Baltimore, MD, USA.
Anand JillellaDepartment of Medicine, Georgia Regents University, Augusta, GA, USA.
Daniel J DeAngeloHematologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Solveig G EricsonNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Felice LinNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Ghulam WarsiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Jerald RadichClinical Cancer Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Novartis (United States) · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USGeorgia Regents Medical Center · USIndiana Cancer Consortium · USMayo Clinic in Florida · USSaint Agnes Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe phase II, exploratory, open-label Exploring Nilotinib

methodsPatients with CML-CP who had previously achieved a complete cytogenetic response (CCyR), but had a suboptimal molecular response, with frontline imatinib therapy (

resultsAt 3 months after switching to nilotinib, 10 of 17 (59%) evaluable patients had achieved MMR. At 12 months, 9 of 12 (75%) evaluable patients had achieved MMR, and the median

conclusionsOverall, results from this exploratory study suggest that switching to nilotinib due to suboptimal molecular response with imatinib can result in improved molecular response for patients with CML-CP.

Indexed as

CML-CPENABLimatinibnilotinibsuboptimal responseswitchtyrosine kinase inhibitor

Identifiers

PMID28042454
PMCPMC5167080
OpenAlexW2551124788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.